Satoris Solution: Biomarkers for Alzheimer’s Disease

Until now, no one has developed Alzheimer's disease (AD) biomarkers that are:

• Highly specific and sensitive (>80%)1
• Predictive of earliest stages of disease1
• Non-invasive, reliable, reproducible, and simple to perform¹

Figure 1: The Satoris biomarker discovery process.

In response to this need, Satoris has demonstrated a simple blood test that uses 18 protein biomarkers to identify AD and Mild Congnitive Impairment (MCI) that will progress to AD.

The results of a blind study on the Satoris test were published in Nature Medicine, October 2007. In that study, 259 samples were analyzed. The Satoris test was shown to be ~90% accurate in diagnosing AD versus normal subjects, as well as ~90% accurate in distinguishing AD from other dementias.

Figure 2: Identifying Alzheimer's Disease and discriminating Alzheimer's disease from other dementias.

Figure 3: Early identification of Alzheimer's disease in at-risk MCI patients.

To date, over 1,000 samples have been analyzed in the course of identifying and developing this panel of biomarkers. Satoris is now readying the test for commercialization.

¹Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease.” The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association, Chicago, IL and the National Institute on Aging, Bethesda, MD.